JP2005510244A5 - - Google Patents

Download PDF

Info

Publication number
JP2005510244A5
JP2005510244A5 JP2003547621A JP2003547621A JP2005510244A5 JP 2005510244 A5 JP2005510244 A5 JP 2005510244A5 JP 2003547621 A JP2003547621 A JP 2003547621A JP 2003547621 A JP2003547621 A JP 2003547621A JP 2005510244 A5 JP2005510244 A5 JP 2005510244A5
Authority
JP
Japan
Prior art keywords
protein
expression construct
vaccine
flavivirus
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003547621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510244A (ja
Filing date
Publication date
Priority claimed from AUPR9093A external-priority patent/AUPR909301A0/en
Priority claimed from AU2002950974A external-priority patent/AU2002950974A0/en
Application filed filed Critical
Priority claimed from PCT/AU2002/001598 external-priority patent/WO2003046189A1/en
Publication of JP2005510244A publication Critical patent/JP2005510244A/ja
Publication of JP2005510244A5 publication Critical patent/JP2005510244A5/ja
Pending legal-status Critical Current

Links

JP2003547621A 2001-11-26 2002-11-26 フラビウイルスワクチン送達系 Pending JP2005510244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR9093A AUPR909301A0 (en) 2001-11-26 2001-11-26 Flavivirus vaccine system
AU2002950974A AU2002950974A0 (en) 2002-07-29 2002-07-29 Flavivirus vaccine system
PCT/AU2002/001598 WO2003046189A1 (en) 2001-11-26 2002-11-26 Flavivirus vaccine delivery system

Publications (2)

Publication Number Publication Date
JP2005510244A JP2005510244A (ja) 2005-04-21
JP2005510244A5 true JP2005510244A5 (enExample) 2006-01-19

Family

ID=25646850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003547621A Pending JP2005510244A (ja) 2001-11-26 2002-11-26 フラビウイルスワクチン送達系

Country Status (7)

Country Link
US (1) US20060204523A1 (enExample)
EP (1) EP1461441A4 (enExample)
JP (1) JP2005510244A (enExample)
CN (1) CN100392087C (enExample)
CA (1) CA2467397A1 (enExample)
NZ (1) NZ533237A (enExample)
WO (1) WO2003046189A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072274A1 (en) * 2003-01-30 2004-08-26 Shanghai Tengen Biomedical Co., Ltd. Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
AU2004245578B2 (en) * 2003-06-06 2008-10-30 Replikun Biotech Pty Ltd Flavivirus replicon packaging system
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
US20070036827A1 (en) * 2003-10-29 2007-02-15 The University Of Queensland West nile virus vaccine
EP1991709B1 (en) 2006-02-27 2017-01-25 The Board of Regents of The University of Texas System Pseudoinfectious flavivirus and uses thereof
UA103316C2 (uk) 2008-03-14 2013-10-10 Санофі Пастер Біолоджікс Ко. Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
EP2408477A4 (en) * 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
NZ606591A (en) * 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
HRP20191535T1 (hr) * 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cjepiva protiv raka
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
BE1023557B1 (fr) 2014-02-10 2017-05-03 Univercells Sa Systeme, appareil et procede pour la production de biomolecules
WO2017053851A1 (en) * 2015-09-23 2017-03-30 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
BR112019016309A2 (pt) * 2017-02-14 2020-03-31 The Board Of Regents Of The University Of Texas System Vírus da zika atenuado vivo com deleção 3'utr, vacina contendo o mesmo e uso da mesma
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
BR112022010932A2 (pt) * 2019-12-03 2022-09-06 Council Queensland Inst Medical Res Partículas interferentes defeituosas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2345614T3 (es) * 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
CA2311395C (en) * 1997-11-28 2006-11-28 Replikun Biotech Pty Ltd Flavivirus expression and delivery system
EP1108036B1 (en) * 1998-09-02 2010-06-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dengue viruses that are replication defective in mosquitos for use as vaccines
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
JP5480458B2 (ja) * 1999-08-09 2014-04-23 サンド・アクチエンゲゼルシヤフト 自己タンパク質分解切断によるタンパク質の製造
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US7094411B2 (en) * 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Similar Documents

Publication Publication Date Title
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
JP4504464B2 (ja) キメラフラビウイルスワクチン
JP4656794B2 (ja) 無毒性の免疫原性フラビウイルスキメラ
US8088391B2 (en) West nile virus vaccine
JP2005510244A5 (enExample)
CA2567254C (en) Tc-83-derived alphavirus vectors, particles and methods
Gehrke et al. Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line
McAllister et al. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases
RU2527891C2 (ru) Флавивирус с двухкомпонентным геномом и его использование
EP1366170A1 (en) Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
AU2002235678A1 (en) Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
Bonaldo et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
NZ533237A (en) Flavivirus vaccine delivery system
CN101018860A (zh) 黄病毒疫苗
JP2006526393A5 (enExample)
WO2004072274A1 (en) Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
JP7663250B2 (ja) ラッサウイルスワクチン
WO2005040390A1 (en) A recombinant vaccine using yellow fever virus as vector
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
CN111343998B (zh) 哺乳动物特异性的生长缺陷的虫媒病毒
Roby et al. Nucleic acid-based infectious and pseudo-infectious flavivirus vaccines
US20220402976A1 (en) Chimeric filovirus vaccines
OA20659A (en) Chimeric filovirus vaccines.
HK1083192B (en) West nile virus vaccine